UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Physical Mundane as Topos: Walking/Dwelling/Using as Rhetorical Invention

College composition and communication, 2016-12, Vol.68 (2), p.266-291

Bacha, Jeffrey A.

2016

Volltextzugriff (PDF)

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials

Neuro-oncology (Charlottesville, Va.), 2021-02, Vol.23 (2), p.189-198

2021

Volltextzugriff (PDF)

Abstract 2157: Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2157-2157

2016

Volltextzugriff (PDF)

Taxonomies, Folksonomies, and Semantics: Establishing Functional Meaning in Navigational Structures

Journal of technical writing and communication, 2012-07, Vol.42 (3), p.249-263

Bacha, Jeffrey A.

2012

Volltextzugriff (PDF)

Mapping Use, Storytelling, and Experience Design: User-Network Tracking as a Component of Usability and Sustainability

Journal of business and technical communication, 2018-04, Vol.32 (2), p.198-228

Bacha, Jeffrey A.

2018

Volltextzugriff (PDF)

Mapping Use, Storytelling, and Experience Design

Journal of business and technical communication, 2018-04, Vol.32 (2), p.198-228

Bacha, Jeffrey A

2018

Volltextzugriff (PDF)

Abstract 1369: Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1369-1369

2020

Volltextzugriff (PDF)

A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS10073-TPS10073

2023

Volltextzugriff (PDF)

A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS10063-TPS10063

2022

Volltextzugriff (PDF)

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT154-CT154

2020

Volltextzugriff (PDF)

Abstract A01: Distinct mechanism of action of DNA-damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors

Clinical cancer research, 2018-08, Vol.24 (15_Supplement), p.A01-A01

2018

Volltextzugriff (PDF)

Abstract 900: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.900-900

2018

Volltextzugriff (PDF)

Abstract 1962: Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1962-1962

2018

Volltextzugriff (PDF)

Abstract 5231: Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different (epi)genetic background and treatment history

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5231-5231

2020

Volltextzugriff (PDF)

Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A109-A109

2018

Volltextzugriff (PDF)

Abstract 1429: DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1429-1429

2017

Volltextzugriff (PDF)

Abstract 2483: Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming chemoresistance in glioblastoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2483-2483

2017

Volltextzugriff (PDF)

Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT273-CT273

2020

Volltextzugriff (PDF)

Abstract CT054: Phase II study of dianhydrogalactitol in patients with MGMT -unmethylated bevacizumab-naive recurrent glioblastoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT054-CT054

2017

Volltextzugriff (PDF)

Abstract NTOC-108: ACTIVITY OF DIANHYDROGALACTITOL (VAL–083) IN OVARIAN TUMOR MODELS, SENSITIVE OR RESISTANT TO CISPLATIN

Clinical cancer research, 2017-06, Vol.23 (11_Supplement), p.NTOC-108-NTOC-108

2017

Volltextzugriff (PDF)

Abstract A51: Dianhydrogalactitol (VAL-083) offers potential therapeutic alternatives in the treatment of pediatric brain tumors

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (5_Supplement), p.A51-A51

2016

Volltextzugriff (PDF)

Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT272-CT272

2020

Volltextzugriff (PDF)

Abstract 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.751-751

2015

Volltextzugriff (PDF)

Activity of dianhydrogalactitol alone or with platinum drugs against non-small cell lung cancer cell lines

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e19145-e19145

2015

Volltextzugriff (PDF)

Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS2082-TPS2082

2017

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Englisch
(157)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Humans
(32)
Cardiac & Cardiovascular Systems
(22)
Cardiovascular System & Cardiology
(22)
Child
(13)
Pediatrics
(13)
Abstracts
(12)
Heart Defects, Congenital - Surgery
(12)
Male
(10)
Congenital Heart Disease
(9)
Infant
(9)
Infant, Newborn
(9)
Surgery
(9)
Female
(8)
Treatment Outcome
(8)
Biological And Medical Sciences
(6)
Child, Preschool
(6)
Medical Sciences
(6)
Outcomes
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Physical Mundane as Topos: Walking/Dwelling/Using as Rhetorical Invention

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials

Abstract 2157: Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance

Taxonomies, Folksonomies, and Semantics: Establishing Functional Meaning in Navigational Structures

Mapping Use, Storytelling, and Experience Design: User-Network Tracking as a Component of Usability and Sustainability

Mapping Use, Storytelling, and Experience Design

Abstract 1369: Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells

A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors

A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer

Abstract A01: Distinct mechanism of action of DNA-damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors

Abstract 900: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Abstract 1962: Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy

Abstract 5231: Dianhydrogalactitol (VAL-083) exhibits strong efficacy in GBM tumors with different (epi)genetic background and treatment history

Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors

Abstract 1429: DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells

Abstract 2483: Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming chemoresistance in glioblastoma

Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma

Abstract CT054: Phase II study of dianhydrogalactitol in patients with MGMT -unmethylated bevacizumab-naive recurrent glioblastoma

Abstract NTOC-108: ACTIVITY OF DIANHYDROGALACTITOL (VAL–083) IN OVARIAN TUMOR MODELS, SENSITIVE OR RESISTANT TO CISPLATIN

Abstract A51: Dianhydrogalactitol (VAL-083) offers potential therapeutic alternatives in the treatment of pediatric brain tumors

Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting

Abstract 751: In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer

Activity of dianhydrogalactitol alone or with platinum drugs against non-small cell lung cancer cell lines

Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma

Suchergebnisse filtern